Mycobacterium tuberculosis is a serious, but rare infectious complication after allogeneic bone marrow transplantation. We describe a case of fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation for Philadelphia chromosomepositive ALL. The diagnosis was made after BAL. Although broad-spectrum antituberculous therapy was started immediately after diagnosis, blood cultures became positive for Mycobacterium tuberculosis. The patient developed severe pyrexias and finally died of multi-organ failure. Rapid progression of mycobacterial infection should be considered in patients post BMT with unexplained fever, particularly in patients from endemic areas. Bone Marrow Transplantation (2001) 27, 217-218. Keywords: Mycobacterium tuberculosis; graft-versushost disease; sepsis; bone marrow transplantation Mycobacterial infections are generally seen in patients with impaired cell-mediated immunity. As bone marrow transplant patients, especially those with GVHD, belong to this group, a high incidence might be anticipated. However, in comparison with solid organ transplant recipients, mycobacterial infection after allogeneic bone marrow transplantation is an uncommon complication.
Mycobacterial infections are generally seen in patients with impaired cell-mediated immunity. As bone marrow transplant patients, especially those with GVHD, belong to this group, a high incidence might be anticipated. However, in comparison with solid organ transplant recipients, mycobacterial infection after allogeneic bone marrow transplantation is an uncommon complication. 1 Once the diagnosis is made, appropriate local measures and therapy with antimycobacterial medications usually result in complete resolution. To our knowledge, there are no previous reports of fatal sepsis due to Mycobacterium tuberculosis.
Case report
A 34-year-old Russian born male was diagnosed with Philadelphia chromosome-positive pre-B-ALL in February 1999. After two cycles of induction chemotherapy, including methotrexate/asparaginase and high-dose cytosine arabinoside/mitoxantrone, he underwent allogeneic BMT from an HLA-compatible unrelated donor in July 1999. A pretransplant chest radiograph showed no abnormalities suggesting mycobacterial infection. The patient therefore received no anti-TB prophylaxis despite a positive family history. A skin test was not performed. Conditioning consisted of total body irradiation, cyclophosphamide and ATG (TBI/Cy/ATG). GVHD prophylaxis was cyclosporin A (CsA) plus methotrexate. His post-transplant course was complicated by GVHD of liver and skin (grade II) which was treated with prednisone (2 mg/kg bodyweight). In addition, he developed signs of interstitial pneumonia and a bronchoalveolar lavage (BAL) was performed. Cultures taken were found to be positive for CMV. Therapy with foscarnet and CMV-IVIg was started and his pneumonia resolved.
In August 1999 the patient was readmitted for CMV reactivation with high grade fever and fatigue while he was still being treated with CsA and prednisone. Physical examination was normal, laboratory tests revealed leukopenia with 2200 leukocytes/l (3% myelocytes, 6% metamyelocytes, 86% granulocytes, 3% monocytes and 0% lymphocytes; Ig levels were normal) and elevated liver enzymes. Chest X-ray was normal. Despite ongoing foscarnet therapy there was an increase of leukocytes positive for the CMVspecific antigen pp65 (from 28 to 92 per 200 000 polymorphonuclear leukocytes). Therefore, CMV-specific therapy was switched from foscarnet to ganciclovir. In addition, broad-spectrum antibiotics were started because of FUO. The fever resolved, but during ganciclovir treatment the patient became increasingly leukopenic (700/l). Five days later he again developed a fever of 40°C and complained of shortness of breath. He had normal breath sounds, but his respiratory rate was increased and an arterial blood gas showed severe hypoxia (pH 7.50, pCO 2 25.78 mmHG, pO 2 51.2 mmHg, base excess 1.7 mmol/l, oxygen saturation 89.6%). A high resolution CT revealed two small pulmonary infiltrates (left lower and right middle lobe). Further antibiotics were added, but his respiratory function worsened dramatically. A chest X-ray 2 days later showed diffuse bilateral infiltration (Figure 1) . He was transferred to the intensive care unit, intubated and ventilated. A BAL was performed. A Gram stain revealed no pathogens, but the Ziehl-Neelson stain showed many acid-fast bacilli (Figure 2) . Therapy with rifampicin, ethambutol, isoniazid, pyrazinamide and streptomycin was started. The bacteria were identified as Mycobacterium tuberculosis by success- ful PCR amplification directly from the BAL. Despite the anti-tuberculous therapy the patient did not improve. He developed temperatures and blood cultures became positive for Mycobacterium tuberculosis. Five days later he died of multi-organ failure. Eleven days later the PCR result was confirmed by conventional microbiological methods. Susceptibility testing showed that the strain had been susceptible to all the anti-tuberculous drugs except for streptomycin. The BAL, performed 6 weeks prior to this admission had been culture negative for Mycobacterium tuberculosis.
Discussion
Patients with impaired cell-mediated immunity are at high risk of severe infectious complications. In bone marrow transplant patients major causes are viral infections such as CMV or VZV. 2 In contrast to patients who receive solid organ transplantation, 1 mycobacterial infections are rare in BMT recipients. In a 20-year retrospective review mycobacterial infections were identified in only nine of 1486 allogeneic transplant patients (prevalence 0.6%). 3 A recent report described four patients with Mycobacterium tuberculosis out of 641 adult transplant patients (two had coexisting CMV infection). The range of onset was between 120 days and 20 months post transplant. 4 However, in a single center study from Turkey, where tuberculosis is endemic, a 30 to 40 times higher incidence in BMT patients compared to the general Turkish population was detected. 5 The patient described here died of fulminant tuberculous sepsis. Because of his acute GVHD (grade II) he was receiving immunosuppressive therapy with CsA and prednisone. His course was further complicated by known CMV reactivation and the history of former culture-positive CMV pneumonia. Although diagnosed only 1 day after the BAL was carried out and although he was immediately treated with appropriate therapy, progressive infection could not be stopped. Apart from the immunosuppression, additional risk factors for developing tuberculosis were a positive family history and growing up for almost 20 years in an endemic country before onset of his disease.
In conclusion, rapid progression of mycobacterial infection should be considered early in the differential diagnosis of patients post BMT with unexplained fever, particularly in patients from endemic countries or with a positive family history. In patients who have received previous BacilleCalmette Guerin immunotherapy or in those with inadequately treated tuberculosis a skin test should be performed and, when this tests positive, antituberculotic prophylaxis should be considered.
